# AxoGen

Type: Company (AXGN)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/axogen
Canonical HTML page: https://gethealthbrief.com/entity/axogen

## Recent coverage (2 stories)

### DAFNA Capital Trims Axogen Stake Amid 71% Stock Surge and Strong Revenue Growth
2026-03-22 04:25:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, following a period of significant outperformance. Despite the trim, Axogen remains a core holding for the fund as the medical device maker continues to capitalize on its 20% revenue growth and dominant position in the peripheral nerve repair market.
Full story: https://gethealthbrief.com/story/dafna-capital-axogen-trim-analysis

### Wells Fargo Upgrades AxoGen to Strong-Buy as Nerve Repair Market Gains Momentum
2026-02-21 01:11:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AxoGen (NASDAQ: AXGN) has received a significant rating upgrade to "Strong-Buy" from Wells Fargo, signaling robust institutional confidence in the peripheral nerve repair specialist. This move, coupled with price target hikes from Jefferies and positive outlooks from Citigroup, underscores a bullish sentiment for the company's clinical and commercial trajectory.
Full story: https://gethealthbrief.com/story/axogen-wells-fargo-strong-buy-upgrade

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.